Compare TPC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | MIRM |
|---|---|---|
| Founded | 1894 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | N/A | 2019 |
| Metric | TPC | MIRM |
|---|---|---|
| Price | $68.30 | $72.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $82.00 | ★ $82.82 |
| AVG Volume (30 Days) | 540.3K | ★ 593.2K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,103,323,000.00 | $471,794,000.00 |
| Revenue This Year | $24.11 | $53.14 |
| Revenue Next Year | $11.90 | $19.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 19.22 | ★ 53.66 |
| 52 Week Low | $18.34 | $36.88 |
| 52 Week High | $77.00 | $78.55 |
| Indicator | TPC | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 55.55 |
| Support Level | $58.11 | $71.04 |
| Resistance Level | $63.60 | $73.50 |
| Average True Range (ATR) | 2.62 | 2.74 |
| MACD | 0.70 | 0.33 |
| Stochastic Oscillator | 98.02 | 78.35 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.